Additive Effect of Supratarsal Olopatadine HCL 0.1% Injection In Patients of Vernal Keratoconjunctivitis On Topical Olopatadine
Zeeshan Kamil, Qirat Qurban, Shela Dareshani
To assess the additional effect of supratarsal injection of olopatadine in patients suffering from vernal keratoconjunctivitis, with concurrent use of topical olopatadine.
Study design •
Place & Duration of study
BHY Hospital Karachi, from May 2019 to October 2019.
Group A included patients who were on topical treatment with olopatadine, whereas Group B included those who were on topical treatment with olopatadine as well as receiving single adjuvant supratarsal injection of olopatadine. The supportive treatment was similar in both the groups. Follow up was done on seventh and fourteenth day for the resolution of sign and symptoms. Statistical analysis was done with SPSS version 25.0. Chi square test was used to find out significance of treatment outcome. A p < 0.05 was considered as significant.
This study recruited 40 patients with age from 8 year to 16 year. Two groups with 20 patients in each were made. The mean age of the patients was 12.27±2.76 year. There were 26 (65%) males and fourteen (35%) females. All patients had bilateral involvement with almost similar clinical signs and symptoms. After fourteen days nine (45%) patients in group A, and 17 (85%) in group B had excellent results. This was found significant with p =0.027.
An additive effect of supra tarsal olopatadine injection with topical olopatadine eye drops had a statistically significant effect on the outcome in patients with vernal keratoconjunctivitis.
Supratarsal olopatadine, Topical olopatadine, Olopatadine, Vernal keratoconjunctivitis.